The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age
Identifieur interne : 001321 ( Istex/Corpus ); précédent : 001320; suivant : 001322The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age
Auteurs : Yoshio Hirota ; Masaro Kaji ; Saburo Ide ; Shuro Goto ; Tetsuya OkaSource :
- Vaccine [ 0264-410X ] ; 1996.
English descriptors
- Teeft :
- Achievement rate, Achievement rates, Antibody, Antibody induction, Antibody response, Antibody responses, Attack rate ratio, Attack survey, Attenuated influenza, Confidence interval, Difference method, Elderly persons, Entire sample, Epidemic peak, Greater rise, Greater titer, Greater titer rise, Healthy adults, Hirota, Hlnl, Independent effect, Independent effects, Influenza, Influenza vaccine, Influenza vaccines, Interaction term, Japanese scale, Multivac, Multivac group, Multivac groups, National institute, Other hand, Poor antibody response, Poor response, Postvaccination, Postvaccination sera, Postvaccination titer, Potential predictors, Preexisting antibody, Present study, Prevac titerxage, Prevaccination, Prevaccination antibody, Prevaccination table, Prevaccination titer, Prevaccination titer levels, Prevaccination titers, Previous studies, Previous vaccinations, Protective level, Rank test, Response rate, Response rates, Serum antibody, Significant effect, Study subjects, Titer, Titer rise, Trend test, Unbalanced data, Vaccination, Vaccination history, Vaccine, Vaccine antigens, Vaccine efficacy, Vaccine strain, Variance, Virus vaccines, Wilcoxon rank, Wilcoxon test.
Abstract
Abstract: The immunogenicity of the trivalent split-virus influenza vaccine was investigated among 70 healthy adults (mean age: 48.5, range: 36–68). The vaccine antigens were: A/Yamagata/32/89 (H1N1); A/Beijing/352/89 (H3N2); and B/Bangkok/163/90. Regarding the entire sample, the vaccine induced a tenfold or more rise on the average in the hemagglutination inhibition (HAI) antibody to each antigen. The response rates (greater than or equal to a fourfold rise) were about 90% or more among those with a prevaccination titer ≤1:64 (equivalent to ≤1:16 on the Western scale: in Japan, the HAI titers are expressed by the final, and not the initial, dilution of the serum; from hereon our findings will be expressed using the Japanese scale), whereas they were 0–50% at ≥1:128. Thus, the prevaccination titer was negatively associated with antibody induction. The achievement rates (postvaccination titer ≥1:128) among those with a prevaccination titer <1:16 remained at 48–68%. Regarding the analysis of variance, a significant effect on antibody induction was indicated for the prevaccination titer (P≤0.002), but not for age (P≥0.425). The interaction between the prevaccination titer and age was significant for A/Yamagata (P=0.030), while it was also suggestive for A/Beijing (P=0.054): as age increased, those with no preexisting antibody (<1:16) showed greater titer rises, in contrast to the smaller rises among those with a titer ≥1:16. Based on the attack survey conducted separately, the vaccine efficacy on influenza-like illnesses with fever ≥37°C and ≥37.5°C was calculated to be 16% (95% confidence interval: −66% to 57%) and 37% (−55% to 74%), respectively.
Url:
DOI: 10.1016/S0264-410X(96)00153-3
Links to Exploration step
ISTEX:54CB1E6B488CBF8626F2DF25D03ACD77B6AA34A7Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age</title><author><name sortKey="Hirota, Yoshio" sort="Hirota, Yoshio" uniqKey="Hirota Y" first="Yoshio" last="Hirota">Yoshio Hirota</name><affiliation><mods:affiliation>Department of Public Health, Faculty of Medicine 60, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kaji, Masaro" sort="Kaji, Masaro" uniqKey="Kaji M" first="Masaro" last="Kaji">Masaro Kaji</name><affiliation><mods:affiliation>Kurume University, Asahi-machi, Kurume-shi, Japan</mods:affiliation></affiliation></author><author><name sortKey="Ide, Saburo" sort="Ide, Saburo" uniqKey="Ide S" first="Saburo" last="Ide">Saburo Ide</name><affiliation><mods:affiliation>Department of Public Health, Faculty of Medicine 60, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Goto, Shuro" sort="Goto, Shuro" uniqKey="Goto S" first="Shuro" last="Goto">Shuro Goto</name><affiliation><mods:affiliation>The Chemo-Sero-Therapeutic Research Institute, Okubo 1-6-1, Kurnamoto, Japan</mods:affiliation></affiliation></author><author><name sortKey="Oka, Tetsuya" sort="Oka, Tetsuya" uniqKey="Oka T" first="Tetsuya" last="Oka">Tetsuya Oka</name><affiliation><mods:affiliation>The Chemo-Sero-Therapeutic Research Institute, Okubo 1-6-1, Kurnamoto, Japan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:54CB1E6B488CBF8626F2DF25D03ACD77B6AA34A7</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1016/S0264-410X(96)00153-3</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-VSM1PWWF-B/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001321</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001321</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age</title><author><name sortKey="Hirota, Yoshio" sort="Hirota, Yoshio" uniqKey="Hirota Y" first="Yoshio" last="Hirota">Yoshio Hirota</name><affiliation><mods:affiliation>Department of Public Health, Faculty of Medicine 60, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kaji, Masaro" sort="Kaji, Masaro" uniqKey="Kaji M" first="Masaro" last="Kaji">Masaro Kaji</name><affiliation><mods:affiliation>Kurume University, Asahi-machi, Kurume-shi, Japan</mods:affiliation></affiliation></author><author><name sortKey="Ide, Saburo" sort="Ide, Saburo" uniqKey="Ide S" first="Saburo" last="Ide">Saburo Ide</name><affiliation><mods:affiliation>Department of Public Health, Faculty of Medicine 60, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Goto, Shuro" sort="Goto, Shuro" uniqKey="Goto S" first="Shuro" last="Goto">Shuro Goto</name><affiliation><mods:affiliation>The Chemo-Sero-Therapeutic Research Institute, Okubo 1-6-1, Kurnamoto, Japan</mods:affiliation></affiliation></author><author><name sortKey="Oka, Tetsuya" sort="Oka, Tetsuya" uniqKey="Oka T" first="Tetsuya" last="Oka">Tetsuya Oka</name><affiliation><mods:affiliation>The Chemo-Sero-Therapeutic Research Institute, Okubo 1-6-1, Kurnamoto, Japan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996">1996</date><biblScope unit="volume">14</biblScope><biblScope unit="issue">17–18</biblScope><biblScope unit="page" from="1597">1597</biblScope><biblScope unit="page" to="1602">1602</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Achievement rate</term><term>Achievement rates</term><term>Antibody</term><term>Antibody induction</term><term>Antibody response</term><term>Antibody responses</term><term>Attack rate ratio</term><term>Attack survey</term><term>Attenuated influenza</term><term>Confidence interval</term><term>Difference method</term><term>Elderly persons</term><term>Entire sample</term><term>Epidemic peak</term><term>Greater rise</term><term>Greater titer</term><term>Greater titer rise</term><term>Healthy adults</term><term>Hirota</term><term>Hlnl</term><term>Independent effect</term><term>Independent effects</term><term>Influenza</term><term>Influenza vaccine</term><term>Influenza vaccines</term><term>Interaction term</term><term>Japanese scale</term><term>Multivac</term><term>Multivac group</term><term>Multivac groups</term><term>National institute</term><term>Other hand</term><term>Poor antibody response</term><term>Poor response</term><term>Postvaccination</term><term>Postvaccination sera</term><term>Postvaccination titer</term><term>Potential predictors</term><term>Preexisting antibody</term><term>Present study</term><term>Prevac titerxage</term><term>Prevaccination</term><term>Prevaccination antibody</term><term>Prevaccination table</term><term>Prevaccination titer</term><term>Prevaccination titer levels</term><term>Prevaccination titers</term><term>Previous studies</term><term>Previous vaccinations</term><term>Protective level</term><term>Rank test</term><term>Response rate</term><term>Response rates</term><term>Serum antibody</term><term>Significant effect</term><term>Study subjects</term><term>Titer</term><term>Titer rise</term><term>Trend test</term><term>Unbalanced data</term><term>Vaccination</term><term>Vaccination history</term><term>Vaccine</term><term>Vaccine antigens</term><term>Vaccine efficacy</term><term>Vaccine strain</term><term>Variance</term><term>Virus vaccines</term><term>Wilcoxon rank</term><term>Wilcoxon test</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The immunogenicity of the trivalent split-virus influenza vaccine was investigated among 70 healthy adults (mean age: 48.5, range: 36–68). The vaccine antigens were: A/Yamagata/32/89 (H1N1); A/Beijing/352/89 (H3N2); and B/Bangkok/163/90. Regarding the entire sample, the vaccine induced a tenfold or more rise on the average in the hemagglutination inhibition (HAI) antibody to each antigen. The response rates (greater than or equal to a fourfold rise) were about 90% or more among those with a prevaccination titer ≤1:64 (equivalent to ≤1:16 on the Western scale: in Japan, the HAI titers are expressed by the final, and not the initial, dilution of the serum; from hereon our findings will be expressed using the Japanese scale), whereas they were 0–50% at ≥1:128. Thus, the prevaccination titer was negatively associated with antibody induction. The achievement rates (postvaccination titer ≥1:128) among those with a prevaccination titer <1:16 remained at 48–68%. Regarding the analysis of variance, a significant effect on antibody induction was indicated for the prevaccination titer (P≤0.002), but not for age (P≥0.425). The interaction between the prevaccination titer and age was significant for A/Yamagata (P=0.030), while it was also suggestive for A/Beijing (P=0.054): as age increased, those with no preexisting antibody (<1:16) showed greater titer rises, in contrast to the smaller rises among those with a titer ≥1:16. Based on the attack survey conducted separately, the vaccine efficacy on influenza-like illnesses with fever ≥37°C and ≥37.5°C was calculated to be 16% (95% confidence interval: −66% to 57%) and 37% (−55% to 74%), respectively.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>prevaccination</json:string><json:string>vaccine</json:string><json:string>prevaccination titer</json:string><json:string>prevaccination antibody</json:string><json:string>influenza vaccine</json:string><json:string>titer</json:string><json:string>multivac</json:string><json:string>antibody response</json:string><json:string>antibody induction</json:string><json:string>influenza</json:string><json:string>hirota</json:string><json:string>hlnl</json:string><json:string>postvaccination</json:string><json:string>response rate</json:string><json:string>influenza vaccines</json:string><json:string>titer rise</json:string><json:string>present study</json:string><json:string>healthy adults</json:string><json:string>response rates</json:string><json:string>protective level</json:string><json:string>achievement rates</json:string><json:string>postvaccination titer</json:string><json:string>vaccination</json:string><json:string>variance</json:string><json:string>greater titer</json:string><json:string>greater titer rise</json:string><json:string>preexisting antibody</json:string><json:string>attack survey</json:string><json:string>antibody responses</json:string><json:string>achievement rate</json:string><json:string>vaccine strain</json:string><json:string>entire sample</json:string><json:string>virus vaccines</json:string><json:string>antibody</json:string><json:string>vaccination history</json:string><json:string>poor antibody response</json:string><json:string>postvaccination sera</json:string><json:string>serum antibody</json:string><json:string>national institute</json:string><json:string>confidence interval</json:string><json:string>epidemic peak</json:string><json:string>greater rise</json:string><json:string>multivac group</json:string><json:string>japanese scale</json:string><json:string>wilcoxon test</json:string><json:string>wilcoxon rank</json:string><json:string>rank test</json:string><json:string>trend test</json:string><json:string>unbalanced data</json:string><json:string>prevaccination titer levels</json:string><json:string>difference method</json:string><json:string>prevaccination table</json:string><json:string>previous vaccinations</json:string><json:string>independent effects</json:string><json:string>potential predictors</json:string><json:string>multivac groups</json:string><json:string>prevaccination titers</json:string><json:string>other hand</json:string><json:string>independent effect</json:string><json:string>significant effect</json:string><json:string>interaction term</json:string><json:string>prevac titerxage</json:string><json:string>attack rate ratio</json:string><json:string>vaccine efficacy</json:string><json:string>previous studies</json:string><json:string>poor response</json:string><json:string>vaccine antigens</json:string><json:string>study subjects</json:string><json:string>elderly persons</json:string><json:string>attenuated influenza</json:string></teeft></keywords><author><json:item><name>Yoshio Hirota</name><affiliations><json:string>Department of Public Health, Faculty of Medicine 60, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan</json:string></affiliations></json:item><json:item><name>Masaro Kaji</name><affiliations><json:string>Kurume University, Asahi-machi, Kurume-shi, Japan</json:string></affiliations></json:item><json:item><name>Saburo Ide</name><affiliations><json:string>Department of Public Health, Faculty of Medicine 60, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan</json:string></affiliations></json:item><json:item><name>Shuro Goto</name><affiliations><json:string>The Chemo-Sero-Therapeutic Research Institute, Okubo 1-6-1, Kurnamoto, Japan</json:string></affiliations></json:item><json:item><name>Tetsuya Oka</name><affiliations><json:string>The Chemo-Sero-Therapeutic Research Institute, Okubo 1-6-1, Kurnamoto, Japan</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>influenza vaccine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>prevaccination antibody</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>age</value></json:item></subject><arkIstex>ark:/67375/6H6-VSM1PWWF-B</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: The immunogenicity of the trivalent split-virus influenza vaccine was investigated among 70 healthy adults (mean age: 48.5, range: 36–68). The vaccine antigens were: A/Yamagata/32/89 (H1N1); A/Beijing/352/89 (H3N2); and B/Bangkok/163/90. Regarding the entire sample, the vaccine induced a tenfold or more rise on the average in the hemagglutination inhibition (HAI) antibody to each antigen. The response rates (greater than or equal to a fourfold rise) were about 90% or more among those with a prevaccination titer ≤1:64 (equivalent to ≤1:16 on the Western scale: in Japan, the HAI titers are expressed by the final, and not the initial, dilution of the serum; from hereon our findings will be expressed using the Japanese scale), whereas they were 0–50% at ≥1:128. Thus, the prevaccination titer was negatively associated with antibody induction. The achievement rates (postvaccination titer ≥1:128) among those with a prevaccination titer >1:16 remained at 48–68%. Regarding the analysis of variance, a significant effect on antibody induction was indicated for the prevaccination titer (P≤0.002), but not for age (P≥0.425). The interaction between the prevaccination titer and age was significant for A/Yamagata (P=0.030), while it was also suggestive for A/Beijing (P=0.054): as age increased, those with no preexisting antibody (>1:16) showed greater titer rises, in contrast to the smaller rises among those with a titer ≥1:16. Based on the attack survey conducted separately, the vaccine efficacy on influenza-like illnesses with fever ≥37°C and ≥37.5°C was calculated to be 16% (95% confidence interval: −66% to 57%) and 37% (−55% to 74%), respectively.</abstract><qualityIndicators><refBibsNative>true</refBibsNative><abstractWordCount>249</abstractWordCount><abstractCharCount>1673</abstractCharCount><keywordCount>3</keywordCount><score>8.576</score><pdfWordCount>3588</pdfWordCount><pdfCharCount>25205</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>6</pdfPageCount><pdfPageSize>576 x 828 pts</pdfPageSize></qualityIndicators><title>The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age</title><pmid><json:string>9032887</json:string></pmid><pii><json:string>S0264-410X(96)00153-3</json:string></pii><genre><json:string>research-article</json:string></genre><serie><title>Version 6</title><language><json:string>unknown</json:string></language></serie><host><title>Vaccine</title><language><json:string>unknown</json:string></language><publicationDate>1996</publicationDate><issn><json:string>0264-410X</json:string></issn><pii><json:string>S0264-410X(00)X0035-7</json:string></pii><volume>14</volume><issue>17–18</issue><pages><first>1597</first><last>1602</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1992</json:string><json:string>1598</json:string><json:string>1921</json:string><json:string>1990</json:string><json:string>110 to 16/185</json:string><json:string>1991</json:string><json:string>1996</json:string></date><geogName></geogName><orgName><json:string>Japan, the HA</json:string><json:string>Japan, the HAI</json:string><json:string>Chemo-Sero-Therapeutic Research Institute, Okubo I</json:string><json:string>Kyushu University</json:string><json:string>Takeda Chemical Industries Ltd, Osaka</json:string><json:string>National Institute of Health, Japan</json:string><json:string>Department of Public Health, Faculty of Medicine</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>O.Sl</json:string></persName><placeName><json:string>Fukuoka</json:string><json:string>Beijing</json:string><json:string>Bangkok</json:string><json:string>Kumamoto</json:string><json:string>Japan</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Hirota et al.</json:string><json:string>October 1992</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-VSM1PWWF-B</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - medicine, research & experimental</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - virology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Public Health, Environmental and Occupational Health</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Veterinary</json:string><json:string>3 - General Veterinary</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - General Immunology and Microbiology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Molecular Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - techniques d'exploration et de diagnostic (generalites)</json:string></inist></categories><publicationDate>1996</publicationDate><copyrightDate>1996</copyrightDate><doi><json:string>10.1016/S0264-410X(96)00153-3</json:string></doi><id>54CB1E6B488CBF8626F2DF25D03ACD77B6AA34A7</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-VSM1PWWF-B/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-VSM1PWWF-B/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-VSM1PWWF-B/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1996</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note type="content">Section title: Paper</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age</title><author xml:id="author-0000"><persName><forename type="first">Yoshio</forename><surname>Hirota</surname></persName><affiliation>To whom correspondence should be addressed.</affiliation><affiliation>Department of Public Health, Faculty of Medicine 60, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Masaro</forename><surname>Kaji</surname></persName><affiliation>Kurume University, Asahi-machi, Kurume-shi, Japan</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Saburo</forename><surname>Ide</surname></persName><affiliation>Department of Public Health, Faculty of Medicine 60, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Shuro</forename><surname>Goto</surname></persName><affiliation>The Chemo-Sero-Therapeutic Research Institute, Okubo 1-6-1, Kurnamoto, Japan</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Tetsuya</forename><surname>Oka</surname></persName><affiliation>The Chemo-Sero-Therapeutic Research Institute, Okubo 1-6-1, Kurnamoto, Japan</affiliation></author><idno type="istex">54CB1E6B488CBF8626F2DF25D03ACD77B6AA34A7</idno><idno type="ark">ark:/67375/6H6-VSM1PWWF-B</idno><idno type="DOI">10.1016/S0264-410X(96)00153-3</idno><idno type="PII">S0264-410X(96)00153-3</idno></analytic><monogr><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="pISSN">0264-410X</idno><idno type="PII">S0264-410X(00)X0035-7</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996"></date><biblScope unit="volume">14</biblScope><biblScope unit="issue">17–18</biblScope><biblScope unit="page" from="1597">1597</biblScope><biblScope unit="page" to="1602">1602</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1996</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: The immunogenicity of the trivalent split-virus influenza vaccine was investigated among 70 healthy adults (mean age: 48.5, range: 36–68). The vaccine antigens were: A/Yamagata/32/89 (H1N1); A/Beijing/352/89 (H3N2); and B/Bangkok/163/90. Regarding the entire sample, the vaccine induced a tenfold or more rise on the average in the hemagglutination inhibition (HAI) antibody to each antigen. The response rates (greater than or equal to a fourfold rise) were about 90% or more among those with a prevaccination titer ≤1:64 (equivalent to ≤1:16 on the Western scale: in Japan, the HAI titers are expressed by the final, and not the initial, dilution of the serum; from hereon our findings will be expressed using the Japanese scale), whereas they were 0–50% at ≥1:128. Thus, the prevaccination titer was negatively associated with antibody induction. The achievement rates (postvaccination titer ≥1:128) among those with a prevaccination titer <1:16 remained at 48–68%. Regarding the analysis of variance, a significant effect on antibody induction was indicated for the prevaccination titer (P≤0.002), but not for age (P≥0.425). The interaction between the prevaccination titer and age was significant for A/Yamagata (P=0.030), while it was also suggestive for A/Beijing (P=0.054): as age increased, those with no preexisting antibody (<1:16) showed greater titer rises, in contrast to the smaller rises among those with a titer ≥1:16. Based on the attack survey conducted separately, the vaccine efficacy on influenza-like illnesses with fever ≥37°C and ≥37.5°C was calculated to be 16% (95% confidence interval: −66% to 57%) and 37% (−55% to 74%), respectively.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>influenza vaccine</term></item><item><term>prevaccination antibody</term></item><item><term>age</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1996-07-01">Modified</change><change when="1996">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-VSM1PWWF-B/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>JVAC</jid><aid>96001533</aid><ce:pii>S0264-410X(96)00153-3</ce:pii><ce:doi>10.1016/S0264-410X(96)00153-3</ce:doi><ce:copyright type="unknown" year="1996"></ce:copyright></item-info><head><ce:dochead><ce:textfn>Paper</ce:textfn></ce:dochead><ce:title>The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age</ce:title><ce:author-group><ce:author><ce:given-name>Yoshio</ce:given-name><ce:surname>Hirota</ce:surname><ce:cross-ref refid="COR1"><ce:sup>§</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Masaro</ce:given-name><ce:surname>Kaji</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>†</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Saburo</ce:given-name><ce:surname>Ide</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Shuro</ce:given-name><ce:surname>Goto</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>‡</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Tetsuya</ce:given-name><ce:surname>Oka</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>‡</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>a</ce:label><ce:textfn>Department of Public Health, Faculty of Medicine 60, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>b</ce:label><ce:textfn>Kurume University, Asahi-machi, Kurume-shi, Japan</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>c</ce:label><ce:textfn>The Chemo-Sero-Therapeutic Research Institute, Okubo 1-6-1, Kurnamoto, Japan</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>§</ce:label><ce:text>To whom correspondence should be addressed.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="25" month="4" year="1996"></ce:date-received><ce:date-revised day="1" month="7" year="1996"></ce:date-revised><ce:date-accepted day="2" month="7" year="1996"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>The immunogenicity of the trivalent split-virus influenza vaccine was investigated among 70 healthy adults (mean age: 48.5, range: 36–68). The vaccine antigens were: A/Yamagata/32/89 (H1N1); A/Beijing/352/89 (H3N2); and B/Bangkok/163/90. Regarding the entire sample, the vaccine induced a tenfold or more rise on the average in the hemagglutination inhibition (HAI) antibody to each antigen. The response rates (greater than or equal to a fourfold rise) were about 90% or more among those with a prevaccination titer ≤1:64 (equivalent to ≤1:16 on the Western scale: in Japan, the HAI titers are expressed by the final, and not the initial, dilution of the serum; from hereon our findings will be expressed using the Japanese scale), whereas they were 0–50% at ≥1:128. Thus, the prevaccination titer was negatively associated with antibody induction. The achievement rates (postvaccination titer ≥1:128) among those with a prevaccination titer <1:16 remained at 48–68%. Regarding the analysis of variance, a significant effect on antibody induction was indicated for the prevaccination titer (<ce:italic>P</ce:italic>≤0.002), but not for age (<ce:italic>P</ce:italic>≥0.425). The interaction between the prevaccination titer and age was significant for A/Yamagata (<ce:italic>P</ce:italic>=0.030), while it was also suggestive for A/Beijing (<ce:italic>P</ce:italic>=0.054): as age increased, those with no preexisting antibody (<1:16) showed greater titer rises, in contrast to the smaller rises among those with a titer ≥1:16. Based on the attack survey conducted separately, the vaccine efficacy on influenza-like illnesses with fever ≥37°C and ≥37.5°C was calculated to be 16% (95% confidence interval: −66% to 57%) and 37% (−55% to 74%), respectively.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>influenza vaccine</ce:text></ce:keyword><ce:keyword><ce:text>prevaccination antibody</ce:text></ce:keyword><ce:keyword><ce:text>age</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age</title></titleInfo><name type="personal"><namePart type="given">Yoshio</namePart><namePart type="family">Hirota</namePart><affiliation>Department of Public Health, Faculty of Medicine 60, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan</affiliation><description>To whom correspondence should be addressed.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Masaro</namePart><namePart type="family">Kaji</namePart><affiliation>Kurume University, Asahi-machi, Kurume-shi, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Saburo</namePart><namePart type="family">Ide</namePart><affiliation>Department of Public Health, Faculty of Medicine 60, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Shuro</namePart><namePart type="family">Goto</namePart><affiliation>The Chemo-Sero-Therapeutic Research Institute, Okubo 1-6-1, Kurnamoto, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tetsuya</namePart><namePart type="family">Oka</namePart><affiliation>The Chemo-Sero-Therapeutic Research Institute, Okubo 1-6-1, Kurnamoto, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1996</dateIssued><dateModified encoding="w3cdtf">1996-07-01</dateModified><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: The immunogenicity of the trivalent split-virus influenza vaccine was investigated among 70 healthy adults (mean age: 48.5, range: 36–68). The vaccine antigens were: A/Yamagata/32/89 (H1N1); A/Beijing/352/89 (H3N2); and B/Bangkok/163/90. Regarding the entire sample, the vaccine induced a tenfold or more rise on the average in the hemagglutination inhibition (HAI) antibody to each antigen. The response rates (greater than or equal to a fourfold rise) were about 90% or more among those with a prevaccination titer ≤1:64 (equivalent to ≤1:16 on the Western scale: in Japan, the HAI titers are expressed by the final, and not the initial, dilution of the serum; from hereon our findings will be expressed using the Japanese scale), whereas they were 0–50% at ≥1:128. Thus, the prevaccination titer was negatively associated with antibody induction. The achievement rates (postvaccination titer ≥1:128) among those with a prevaccination titer <1:16 remained at 48–68%. Regarding the analysis of variance, a significant effect on antibody induction was indicated for the prevaccination titer (P≤0.002), but not for age (P≥0.425). The interaction between the prevaccination titer and age was significant for A/Yamagata (P=0.030), while it was also suggestive for A/Beijing (P=0.054): as age increased, those with no preexisting antibody (<1:16) showed greater titer rises, in contrast to the smaller rises among those with a titer ≥1:16. Based on the attack survey conducted separately, the vaccine efficacy on influenza-like illnesses with fever ≥37°C and ≥37.5°C was calculated to be 16% (95% confidence interval: −66% to 57%) and 37% (−55% to 74%), respectively.</abstract><note type="content">Section title: Paper</note><subject><genre>Keywords</genre><topic>influenza vaccine</topic><topic>prevaccination antibody</topic><topic>age</topic></subject><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><titleInfo type="abbreviated"><title>JVAC</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1996</dateIssued></originInfo><identifier type="ISSN">0264-410X</identifier><identifier type="PII">S0264-410X(00)X0035-7</identifier><part><date>1996</date><detail type="volume"><number>14</number><caption>vol.</caption></detail><detail type="issue"><number>17–18</number><caption>no.</caption></detail><extent unit="issue-pages"><start>1569</start><end>1718</end></extent><extent unit="pages"><start>1597</start><end>1602</end></extent></part></relatedItem><identifier type="istex">54CB1E6B488CBF8626F2DF25D03ACD77B6AA34A7</identifier><identifier type="ark">ark:/67375/6H6-VSM1PWWF-B</identifier><identifier type="DOI">10.1016/S0264-410X(96)00153-3</identifier><identifier type="PII">S0264-410X(96)00153-3</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-VSM1PWWF-B/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001321 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001321 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:54CB1E6B488CBF8626F2DF25D03ACD77B6AA34A7
|texte= The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age
}}
| This area was generated with Dilib version V0.6.33. |  |